Navigation Links
Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1143 in Ovarian Cancer

LAUSANNE, Switzerland, June 7, 2016 /PRNewswire/ --

Debiopharm International SA (Debiopharm), part of Debiopharm Group, a Swiss-based global biopharmaceutical company, today announced the start of a clinical phase II study to evaluate the IAP inhibitor Debio 1143 for the treatment of Epithelial Ovarian Cancer (EOC) for which it recently received Orphan Drug Designation from both the European Medicine Agency and the Food and Drug Administration.

This study is designed to evaluate the efficacy of Debio 1143 given in combination with Carboplatin and Paclitaxel in a neo-adjuvant setting as compared to chemotherapy alone. Further to encouraging observations made in clinical phase I (NCT01930292), this trial aims at demonstrating the chemosensitizer effect of the compound in a double-blind design and at identifying biomarkers to be used for patients' stratification in pivotal studies. Safety and tolerability of Debio 1143 will also be evaluated by conventional endpoints.

"We are pleased to announce the start of this second phase II trial with Debio 1143 shortly after establishing the recommended dose and encouraging observations for the utility of Debio 1143 in EOC," said Dr Nigel McCracken, Vice President, Clinical Research & Development, Debiopharm International. "It is another illustration of Debiopharm's commitment to improve treatment outcomes for patients suffering from severely debilitating and life threatening conditions".

About Debiopharm International SA 

Debiopharm Group is a Swiss-based global biopharmaceutical group of four companies active in drug development, GMP manufacturing of proprietary drugs, diagnostics, and investment management. Debiopharm International SA is focused on the development of prescription drugs that target unmet medical needs. The company in-licenses and develops promising drug candidates. The products are commercialized by pharmaceutical out-licensing partners to give access to the largest number of patients worldwide.

For more information, please visit

We are on Twitter. Follow us @DebiopharmNews at

Debiopharm International SA Contact
Christelle Tur
Communication Coordinator
Tel: +41(0)21-321-01-11

Additional Media Contacts
In London
Chiara Valsangiacomo
Tel: +44(0)20-7379-5151

In New York
Russo Partners, LLC
Lena Evans
Assistant Vice President 
Tel: +1-212-845-4262

SOURCE Debiopharm Group
Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers
2. Quartz Bio SA Supports Debiopharm Group Precision Medicine Bioinformatics
3. Go To Market Consulting Inc. and Debiopharm Group Collaborate to Identify Early Stage In-licensing Opportunities on the US West Coast
4. Debiopharm Group and TCG Lifesciences Ltd. Enter into an Exclusive Research Agreement to Develop a Novel Class of Antibiotics, a New Strategic Therapeutic Area for Debiopharm
5. Debiopharm Group Announces Completion of Recruitment for Phase III Clinical Study with Triptorelin 22.5 mg in Central Precocious Puberty
6. Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument
7. Debiopharm International SA Initiates Clinical Phase II Study Evaluating Debio 1450 in Staphylococcal Skin Infections
8. Debiopharm International SA Acquires FibroTrap Sample Processing Technology from Spinomix
9. Debiopharm International SA and Solid Biosciences, LLC, Announce a Collaboration to Explore the Use of Alisporivir (Debio 025) in Muscular Dystrophy
10. Die Japanische Krebsgesellschaft und die Debiopharm Group geben die Gewinner des JCA-Mauvernay Awards 2015 bekannt
11. La Japanese Cancer Association y Debiopharm Group anuncian a los ganadores del 2015 JCA-Mauvernay Award
Post Your Comments:
(Date:1/12/2020)... ... January 10, 2020 , ... Nearly 250 Central Valley farmers ... Safe, a stewardship program that promotes effective prevention of accidental pesticide drift from ... officials and high-ranking regulators, participants received training in how to calibrate their equipment, ...
(Date:1/12/2020)... ... January 11, 2020 , ... New Life Hiking Spa ... and information on how to book an affordable option. , Improved health and happiness: ... frenetic pace of everyday life, sight see and a try a new cuisine, the ...
(Date:1/10/2020)... ... January 10, 2020 , ... Reach Higher ... Association, will celebrate high school counselors and award the first annual Excellence in ... Championship weekend and Extra Yard for Teachers Summit celebration on Saturday, January 11th. ...
Breaking Medicine Technology:
(Date:1/27/2020)... ... January 26, 2020 , ... ResMed Launches AirFit F30i, Its First Tube-up Full ... announces the launch of the AirFit F30i, Its First Tube-up Full Face ResMed CPAP ... tube-up or tube-down connection, compact under-the-nose or traditional over-the-nose cushion styles, and even memory ...
(Date:1/24/2020)... (PRWEB) , ... January 24, 2020 , ... ... and managed services company, announced today that it has completed its spin-off of ... generation Healthcare technology cloud products, while Devcool Inc continues its growth and focuses ...
(Date:1/23/2020)... NEW YORK (PRWEB) , ... January 23, 2020 ... ... international leader in medical and scientific training, biomedical research, and patient care—today announced ... by the Office of Gender Equity in Science and Medicine. The awards aim ...
(Date:1/23/2020)... , ... January 23, 2020 , ... ... RespirCare, LLC, a first-of-its-kind, full-service pulmonology clinic based in Tulsa, to provide patients ... agreement, MCNDOH patients will also have access to HGE Health’s digital symptom management ...
(Date:1/23/2020)... ... January 23, 2020 , ... Three leading healthcare ... action to improve diagnostic quality and safety by joining the Coalition to ... in healthcare and patient advocacy. , “Diagnostic error is one of the most ...
Breaking Medicine News(10 mins):